DHG Pharmaceutical JSC 2024 AR2
The report highlights DHG Pharmaceutical Joint Stock Company's performance and strategic initiatives for the fiscal year 2024, marking its 50th anniversary. The company achieved net sales of VND 4,885 billion and profit before tax of VND 904 billion, maintaining its leading position in Vietnam's pharmaceutical industry. Notably, DHG Pharma obtained EU-GMP certification for three production lines at its Non-Betalactam plant and commenced operations at its new Betalactam factory. Additionally, the company demonstrated its commitment to sustainable development by investing in solar energy, organizing community healthcare programs, and allocating over VND 5 billion to social responsibility initiatives.
Company: DHG Pharmaceutical JSC
Sector: Health Care
Country: Vietnam
Year: 2024
Type: AR2
Pages: 115
DHG Pharmaceutical JSC
Annual Report
The report highlights DHG Pharmaceutical Joint Stock Company's performance and strategic initiatives for the fiscal year 2024, marking its 50th anniversary. The company achieved net sales of VND 4,885 billion and profit before tax of VND 904 billion, maintaining its leading position in Vietnam's pharmaceutical industry. Notably, DHG Pharma obtained EU-GMP certification for three production lines at its Non-Betalactam plant and commenced operations at its new Betalactam factory. Additionally, the company demonstrated its commitment to sustainable development by investing in solar energy, organizing community healthcare programs, and allocating over VND 5 billion to social responsibility initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Employees